Small Phase 2 Study Of Daclizumab Shows Benefit Alone And In Combination With Interferon
Researchers report that daclizumab (PDL Biopharma, Inc. and Biogen Idec) alone or in combination with interferon beta reduced disease activity on MRI and improved symptoms in nine people with relapsing-remitting multiple sclerosis*. John W. Rose, MD and colleagues (University of Utah, Salt Lake City) report their findings in the August 21 issue of Neurology (2007;69:785-789).
